In premenopausal women with non-metastatic breast cancer, use of tamoxifen may nearly double the risk of endometrial cancer, researchers report.

Giredestrant significantly improved IDFS in ER-positive, HER2-negative early breast cancer, reducing recurrence or death risk by 30% compared to SOC endocrine therapy. Subgroup analyses showed ...

Menopause after breast cancer can cause symptoms that substantially impact quality of life, making individualized, multidisciplinary care and shared decision-making critical, experts noted during ...